Maxigen Biotech Inc. (TPE:1783)

Market Cap	3.55B -25.0%
Revenue (ttm)	811.56M +19.2%
Net Income	265.31M +39.5%
EPS	2.94 +38.7%
Shares Out	80.69M
PE Ratio	14.95
Forward PE	n/a
Dividend	0.83 (1.89%)
Ex-Dividend Date	Sep 5, 2025

Volume	62,423
Average Volume	75,547
Open	43.00
Previous Close	43.60
Day's Range	43.00 - 43.95
52-Week Range	35.55 - 48.85
Beta	0.29
RSI	50.49
Earnings Date	Mar 20, 2026

About Maxigen Biotech

Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices and cosmetic products in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone materials; beauty care products; and medical devices for ophthalmology, otolaryngology, dental, surgical, orthopedics, and medical aesthetics, as well as engages in collagen purification activities. It also offers ophthalmic vis...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1998
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1783

Financial Performance

In 2025, Maxigen Biotech's revenue was 811.56 million, an increase of 19.23% compared to the previous year's 680.65 million. Earnings were 265.31 million, an increase of 39.52%.